Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study
Pemafibrate is superior to omega-3 fatty acid ethyl in lowering effects of FLI and MASLD in patients with dyslipidemia receiving statin treatment, suggesting that pemafibrate is a beneficial agent for hypertriglyceridemia and reduction of the risk for MASLD.
Authors
- Shinya Hiramitsu
- Mizuho Okada
- Ichiro Sakuma (ORCID: https://orcid.org/0000-0002-3863-0492)
- Naoki Kumashiro (ORCID: https://orcid.org/0000-0002-5432-3599)
- Yasutaka Takeda (ORCID: https://orcid.org/0000-0002-2129-8657)
- Shinichiro Ueda
- Masaru Sakurai (ORCID: https://orcid.org/0000-0002-4929-3225)
- Masato Furuhashi (ORCID: https://orcid.org/0000-0002-0145-3541)
Institutions
- Sapporo Medical University (JP)
- Kanazawa Medical University (JP)
- University of the Ryukyus (JP)
- Hokko Memorial Hospital (JP)
- Nagoya Heart Center (JP)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3389/fendo.2025.1549687
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Kowa Company